180 related articles for article (PubMed ID: 14737093)
1. Inhibition of human non-small cell lung tumors by a c-Met antisense/U6 expression plasmid strategy.
Stabile LP; Lyker JS; Huang L; Siegfried JM
Gene Ther; 2004 Feb; 11(3):325-35. PubMed ID: 14737093
[TBL] [Abstract][Full Text] [Related]
2. High expression of Met/hepatocyte growth factor receptor suppresses tumorigenicity in NCI-H1264 lung carcinoma cells.
To C; Seiden I; Liu N; Wigle D; Tsao MS
Exp Cell Res; 2002 Feb; 273(1):45-53. PubMed ID: 11795945
[TBL] [Abstract][Full Text] [Related]
3. [shRNA-mediated insulin-like growth factor I receptor gene silencing inhibits cell proliferation, induces cell apoptosis, and suppresses tumor growth in non-small cell lung cancer: in vitro and in vivo experiments].
Dong AQ; Kong MJ; Ma ZY; Qian JF; Fan JQ; Xu XH
Zhonghua Yi Xue Za Zhi; 2007 Jun; 87(21):1506-9. PubMed ID: 17785094
[TBL] [Abstract][Full Text] [Related]
4. Constitutive activation of met kinase in non-small-cell lung carcinomas correlates with anchorage-independent cell survival.
Qiao H; Hung W; Tremblay E; Wojcik J; Gui J; Ho J; Klassen J; Campling B; Elliott B
J Cell Biochem; 2002; 86(4):665-77. PubMed ID: 12210733
[TBL] [Abstract][Full Text] [Related]
5. Sp1 regulates expression of MET, and ribozyme-induced down-regulation of MET in fibrosarcoma-derived human cells reduces or eliminates their tumorigenicity.
Liang H; O'Reilly S; Liu Y; Abounader R; Laterra J; Maher VM; McCormick JJ
Int J Oncol; 2004 May; 24(5):1057-67. PubMed ID: 15067326
[TBL] [Abstract][Full Text] [Related]
6. Adenovirus-mediated siRNA targeting c-Met inhibits proliferation and invasion of small-cell lung cancer (SCLC) cells.
Wang ZX; Lu BB; Yang JS; Wang KM; De W
J Surg Res; 2011 Nov; 171(1):127-35. PubMed ID: 20338593
[TBL] [Abstract][Full Text] [Related]
7. Growth inhibition of human papillomavirus 16 DNA-positive mouse tumor by antisense RNA transcribed from U6 promoter.
He Y; Huang L
Cancer Res; 1997 Sep; 57(18):3993-9. PubMed ID: 9307284
[TBL] [Abstract][Full Text] [Related]
8. The scatter factor/hepatocyte growth factor: c-met pathway in human embryonal central nervous system tumor malignancy.
Li Y; Lal B; Kwon S; Fan X; Saldanha U; Reznik TE; Kuchner EB; Eberhart C; Laterra J; Abounader R
Cancer Res; 2005 Oct; 65(20):9355-62. PubMed ID: 16230398
[TBL] [Abstract][Full Text] [Related]
9. Targeting the HGF/SF receptor c-met using a hammerhead ribozyme transgene reduces in vitro invasion and migration in prostate cancer cells.
Davies G; Watkins G; Mason MD; Jiang WG
Prostate; 2004 Sep; 60(4):317-24. PubMed ID: 15264243
[TBL] [Abstract][Full Text] [Related]
10. Targeting the c-Met pathway potentiates glioblastoma responses to gamma-radiation.
Lal B; Xia S; Abounader R; Laterra J
Clin Cancer Res; 2005 Jun; 11(12):4479-86. PubMed ID: 15958633
[TBL] [Abstract][Full Text] [Related]
11. In vivo targeting of SF/HGF and c-met expression via U1snRNA/ribozymes inhibits glioma growth and angiogenesis and promotes apoptosis.
Abounader R; Lal B; Luddy C; Koe G; Davidson B; Rosen EM; Laterra J
FASEB J; 2002 Jan; 16(1):108-10. PubMed ID: 11729097
[TBL] [Abstract][Full Text] [Related]
12. Enhanced therapeutic efficacy of oncolytic herpes vector G207 against human non-small cell lung cancer--expression of an RNA-binding protein, Musashi1, as a marker for the tailored gene therapy.
Kanai R; Eguchi K; Takahashi M; Goldman S; Okano H; Kawase T; Yazaki T
J Gene Med; 2006 Nov; 8(11):1329-40. PubMed ID: 16955534
[TBL] [Abstract][Full Text] [Related]
13. [c-Met and HGF expression in non-small-cell lung carcinomas].
Korobko IV; Zinov'eva MV; Allakhverdiev AK; Zborovskaia IB; Svwrdlov ED
Mol Gen Mikrobiol Virusol; 2007; (2):18-21. PubMed ID: 17598453
[TBL] [Abstract][Full Text] [Related]
14. Antiapoptotic activity of autocrine interleukin-22 and therapeutic effects of interleukin-22-small interfering RNA on human lung cancer xenografts.
Zhang W; Chen Y; Wei H; Zheng C; Sun R; Zhang J; Tian Z
Clin Cancer Res; 2008 Oct; 14(20):6432-9. PubMed ID: 18927282
[TBL] [Abstract][Full Text] [Related]
15. Met receptor overexpression and oncogenic Ki-ras mutation cooperate to enhance tumorigenicity of colon cancer cells in vivo.
Long IS; Han K; Li M; Shirasawa S; Sasazuki T; Johnston M; Tsao MS
Mol Cancer Res; 2003 Mar; 1(5):393-401. PubMed ID: 12651912
[TBL] [Abstract][Full Text] [Related]
16. Antitumor efficacy of oblimersen Bcl-2 antisense oligonucleotide alone and in combination with vinorelbine in xenograft models of human non-small cell lung cancer.
Hu Y; Bebb G; Tan S; Ng R; Yan H; Sartor JR; Mayer LD; Bally MB
Clin Cancer Res; 2004 Nov; 10(22):7662-70. PubMed ID: 15569999
[TBL] [Abstract][Full Text] [Related]
17. Down-regulation of c-Met inhibits growth in the liver of human colorectal carcinoma cells.
Herynk MH; Stoeltzing O; Reinmuth N; Parikh NU; Abounader R; Laterra J; Radinsky R; Ellis LM; Gallick GE
Cancer Res; 2003 Jun; 63(11):2990-6. PubMed ID: 12782608
[TBL] [Abstract][Full Text] [Related]
18. C-Met antisense oligodeoxynucleotide inhibits growth of glioma cells.
Chu S; Yuan X; Li Z; Jiang P; Zhang J
Surg Neurol; 2006 Jun; 65(6):533-8; discussion 538. PubMed ID: 16720163
[TBL] [Abstract][Full Text] [Related]
19. c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions.
Ma PC; Kijima T; Maulik G; Fox EA; Sattler M; Griffin JD; Johnson BE; Salgia R
Cancer Res; 2003 Oct; 63(19):6272-81. PubMed ID: 14559814
[TBL] [Abstract][Full Text] [Related]
20. In vitro c-met inhibition by antisense RNA and plasmid-based RNAi down-modulates migration and invasion of hepatocellular carcinoma cells.
Salvi A; Arici B; Portolani N; Giulini SM; De Petro G; Barlati S
Int J Oncol; 2007 Aug; 31(2):451-60. PubMed ID: 17611703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
